StockData
BioMarin Pharmaceutical Inc logo

BioMarin Pharmaceutical Inc (BMRN) company profile

BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/3093% above fair value
$58.51+0.52 (+0.90%)

Close on Nov 17, 2026Market cap $11.33BP/E 154.0Yield –

About BioMarin Pharmaceutical

Pharmaceutical Preparations, SIC 2834

BioMarin Pharmaceutical Inc. develops and commercializes therapies targeting serious genetic conditions and rare diseases. The biotechnology company organizes its commercial operations into two core business units: Skeletal Conditions and Enzyme Therapies. Key commercial products include VOXZOGO for achondroplasia, alongside enzyme replacement treatments such as VIMIZIM, NAGLAZYME, PALYNZIQ, ALDURAZYME, BRINEURA, and KUVAN. Its customer base consists of specialty pharmacies, hospitals, non-U.S. government entities, pharmaceutical wholesalers, and authorized international distributors, with Sanofi acting as the exclusive distributor and customer for ALDURAZYME.

The company operates globally, conducting direct sales in the United States, Europe, and South America, while serving additional international territories through third-party distribution partners. Its manufacturing infrastructure includes specialized production facilities located in Novato, California, and Shanbally, Cork, Ireland, supplemented by external contract manufacturing organizations. BioMarin Pharmaceutical Inc. maintains its corporate headquarters in San Rafael, California.

Summary of the business section of BioMarin Pharmaceutical's latest annual report, written by StockData.

Company profile

Company

Legal name
BioMarin Pharmaceutical Inc
Founded
1997
Headquarters
Novato, CA
Address
105 Digital Drive 94949
Phone
(415) 506-6700
Employees
3,221, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG LLP, San Francisco, California

Stock & identifiers

Ticker
BMRN
Exchange
Nasdaq
IPO date
Jul 26, 1999
Shares outstanding
194M, Jul 28, 2026
Public float
$6.70B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1048477
CUSIP
09061G101
ISIN
US09061G1013
FIGI
BBG000CZWZ05
Share class FIGI
BBG001S76R05
LEI
NSLL8ITTRR0J5HEMR848
EIN
68-0397820

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Alexander HardyChief Executive Officer, Director214,635
Gregory R. FribergEVP, Chief R&D Officer47,732
George Eric DavisEVP, Chief Legal Officer61,003
Cristin HubbardEVP, Chief Commercial Officer42,472
Charles Greg GuyerEVP, Chief Technical Officer84,140
Brian MuellerEVP, Chief Financial Officer123,314
Rashmi Virendra RamchandaniVP, Chief Accounting Officer25,610
Erin BurkhartGVP, Chief Accounting Officer14,173
Robert M. PlengeDirector6,140
Mark J. EnyedyDirector21,040
Athena CountouriotisDirector21,040
Maykin HoDirector35,500
Willard H. DereDirector46,440
Barbara W. BodemDirector21,045
Robert J. HombachDirector49,360
Elizabeth M. AndersonDirector41,940
Timothy P. WalbertDirector17,686
Ian T. ClarkDirector14,490
Richard A. MeierDirector126,926

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$21.93M$12.21M$6.35M$68$125
FY2024$14.85M$2.42M$6.57M$75$93
FY2023
Alexander Hardy
$17.88M$18.52M$6.32M$110$94
FY2023
Jean Jacques Bienaime
$21.98M$15.76M$6.32M$110$94
FY2022$18.35M$34.38M$6.11M$118$90
FY2021$18.26M$18.39M$5.51M$101$100

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Alexander Hardy
President and CEO
$1.13M$16.83M$1.91M$1.64M$409.36K$21.93M+48%
Brian R. Mueller
Executive Vice President, CFO
$721.15K$4.33M$1.19M$565.50K$22.89K$6.83M+24%
Gregory R. Friberg, M.D.
Executive Vice President, Chief Research & Development Officer
$705.65K$4.62M$1.27M$424.20K$153.20K$7.17M-1%
C. Greg Guyer, Ph.D.
Executive Vice President, Chief Technical Officer
$697.12K$3.46M$954.81K$546.00K$29.59K$5.69M+13%
Cristin Hubbard
Executive Vice President, Chief Commercial Officer
$662.31K$3.46M$954.81K$562.80K$69.62K$5.71M-18%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 3,221 employees worldwide, of whom 1,518 were in operations, 692 were in research and development, 495 were in sales and marketing and 516 were in administration.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?